[Fluimucyl-antibiotic IT: ability of antioxidant therapy for patients with acute attack of infectious chronic obstructive lung disease].

The article presents current views on the role of acid-dependent reactions in the development of daptative and compensative processes of human being. The authors outline oxidative stress as the most important part in the pathogenesis of broncho-pulmonary system diseases. The authors underline in the article the role of non-invasive methods to detect oxidative stress derivates to assess the state of Lipid Peroxidation -AOZ system, carry out differential diagnostics of broncho-obstructive syndrome and monitor the efficacy of anti-inflammatory therapy. The article presents the data on antioxidative systems protecting human body. Complex interconnections between the system generating free-radical compounds and the system utilizing these compound are described in the article. The authors focused on literature data concerning influence of Fluimucyl (N-acetylcysteine) on oxidant-antioxidant system in patients with chronic obstructive lung diseases. The article presents experience results on Fluimucyl-antibiotic IT use in 25 patients with acute attack of stage II and III infectious chronic obstructive lung disease. These results show that Fluimucyl use reduces disease clinical symptoms at the acute stage, normalizes oxidative blood activity (against serum ceruloplasmin level), has positive influence on external respiration indices and eradicates infectious agents causing exacerbation of chronic obstructive lung disease. The study results confirm that combined Fluimucyl-antibiotic IT is a pathogenetic and antioxidative treatment for patients with moderate and severe exacerbation of chronic obstructive lung disease.